Yes, so long as the patient was able to tolerate the treatment and kept to strict dose intervals, then results looked pretty good (very small sample size - 4). The data presented is a little unclear, but shows promise.
The issue with tolerability lead them to develop a gel formulation for future burns trials, which has been used under the SAS with great results so far (the cases they've chosen to present anyway).
Ann: Positive Ph I/II DFI Efficacy Data to Support Site Expansion, page-26
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
30.0¢ |
Change
-0.010(3.23%) |
Mkt cap ! $86.51M | |||
| Open | High | Low | Value | Volume |
| 30.5¢ | 32.0¢ | 29.5¢ | $30.88K | 101.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 21103 | 30.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 32.0¢ | 15000 | 1 |
View Market Depth
| Last trade - 15.59pm 26/06/2025 (20 minute delay) ? |
| RCE (ASX) Chart |